Cencora Inc.


Market Cap$46.76B

Compare Cencora

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Cencora Inc.Cencora Inc.250.85%205%0.25.2
marketMarket Avg49.61.28%30%6.11.1
FinanceFinance Avg11.51.93%13%2.81.5

Earnings Call Q1 2024

January 31, 2024 - AI Summary

Cencora reported strong first quarter results, with revenue up 15% year-over-year to over $72 billion and adjusted earnings per share up 21%.
The company raised its fiscal 2024 full year guidance, reflecting the strength of its business and opportunities in the pharmaceutical market.
Cencora's core pharmaceutical distribution business showed outsized operating income growth, driven by strong volumes, favorable pricing trends, and effective expense management.
The International Healthcare Solutions segment performed well, with Global Specialty Logistics contributing to the strong performance. The company aims to become a leader in this space across major markets.
The company highlighted its focus on ESG goals and initiatives, including employee engagement, diversity and inclusion, and responsible operations.
While geopolitical risks were mentioned, Cencora emphasized its resilience as a healthcare distributor and its ability to navigate challenges in the supply chain. Note: The transcript does not mention specific forecasts, outlooks, dividends, or buybacks.

Current Fair Value

0.4% downside

Overvalued by 0.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$46.76 Billion
Enterprise Value$48.66 Billion
Dividend Yield$1.9876 (0.85%)
Earnings per Share$9.18
Outstanding Shares199,481,993
Avg 30 Day Volume1,542,922


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio25.04
Price to Sales0.18
Price to Book Ratio59.59
Enterprise Value to Revenue0.18
Enterprise Value to EBIT17.37
Enterprise Value to Net Income26
Total Debt to Enterprise0.1
Debt to Equity5.24

Revenue Sources

No data

ESG Score

No data

About CoreSite Realty Corporation

CEO: Paul Szurek